| [1] |
Garlisi B, Lauks S, Aitken C, et al. The Complex Tumor Microenvironment in Ovarian Cancer: Therapeutic Challenges and Opportunities[J]. Curr Oncol, 2024, 31(7):3826-3844. doi: 10.3390/curroncol31070283.
pmid: 39057155
|
| [2] |
Ponton-Almodovar A, Sanderson S, Rattan R, et al. Ovarian tumor microenvironment contributes to tumor progression and chemoresistance[J]. Cancer Drug Resist, 2024, 7:53. doi: 10.20517/cdr.2024.111.
|
| [3] |
Blanc-Durand F, Clemence Wei Xian L, Tan D. Targeting the immune microenvironment for ovarian cancer therapy[J]. Front Immunol, 2023, 14:1328651. doi: 10.3389/fimmu.2023.1328651.
|
| [4] |
Wang Y, Zhu N, Liu J, et al. Role of tumor microenvironment in ovarian cancer metastasis and clinical advancements[J]. J Transl Med, 2025, 23(1):539. doi: 10.1186/s12967-025-06508-0.
pmid: 40369674
|
| [5] |
Zhao F, Jiang X, Li Y, et al. Characterizing tumor biology and immune microenvironment in high-grade serous ovarian cancer via single-cell RNA sequencing: insights for targeted and personalized immunotherapy strategies[J]. Front Immunol, 2024, 15:1500153. doi: 10.3389/fimmu.2024.1500153.
|
| [6] |
Chap BS, Rayroux N, Grimm AJ, et al. Crosstalk of T cells within the ovarian cancer microenvironment[J]. Trends Cancer, 2024, 10(12):1116-1130. doi: 10.1016/j.trecan.2024.09.001.
pmid: 39341696
|
| [7] |
He T, Zhang J, Zeng L, et al. Composite score of PD-1+CD8+ tumor-infiltrating lymphocytes and CD57+CD8+ tumor ascites lymphocytes is associated with prognosis and tumor immune microenvironment of patients with advanced high-grade serous ovarian cancer[J]. Chin J Cancer Res, 2025, 37(1):73-89. doi: 10.21147/j.issn.1000-9604.2025.01.06.
|
| [8] |
Pankowska KA, Będkowska GE, Chociej-Stypułkowska J, et al. Crosstalk of Immune Cells and Platelets in an Ovarian Cancer Microenvironment and Their Prognostic Significance[J]. Int J Mol Sci, 2023, 24(11):9279. doi: 10.3390/ijms24119279.
|
| [9] |
Hathaway CA, Wang T, Townsend MK, et al. Lifetime Exposure to Cigarette Smoke and Risk of Ovarian Cancer by T-cell Tumor Immune Infiltration[J]. Cancer Epidemiol Biomarkers Prev, 2023, 32(1):66-73. doi: 10.1158/1055-9965.EPI-22-0877.
|
| [10] |
Yang H, Chen K, Meng Y, et al. Review: radiotherapy-mediated B cells within the TLS influence the tumor microenvironment[J]. J Immunother Cancer, 2025, 13(7):e011617. doi: 10.1136/jitc-2025-011617.
|
| [11] |
Truxova I, Cibula D, Spisek R, et al. Targeting tumor-associated macrophages for successful immunotherapy of ovarian carcinoma[J]. J Immunother Cancer, 2023, 11(2):e005968. doi: 10.1136/jitc-2022-005968.
|
| [12] |
Hou L, Jiang M, Li Y, et al. Targeting SPP1+ macrophages via the SPP1-CD44 axis reveals a key mechanism of immune suppression and tumor progression in ovarian cancer[J]. Int Immunopharmacol, 2025, 160:114906. doi: 10.1016/j.intimp.2025.114906.
|
| [13] |
Zheng H, Guan X, Meng X, et al. IFN-γ in ovarian tumor microenvironment upregulates HLA-E expression and predicts a poor prognosis[J]. J Ovarian Res, 2023, 16(1):229. doi: 10.1186/s13048-023-01286-z.
pmid: 38007483
|
| [14] |
Hu H, Ma T, Liu N, et al. Immunotherapy checkpoints in ovarian cancer vasculogenic mimicry: Tumor immune microenvironments, and drugs[J]. Int Immunopharmacol, 2022, 111:109116. doi: 10.1016/j.intimp.2022.109116.
|
| [15] |
Ma Q, Kang R, Xu R, et al. Crosstalk between stromal, immune, and ovarian cancer cells in lipid-rich tumor microenvironment exhibits proliferative features[J]. Front Immunol, 2025, 16:1614815. doi: 10.3389/fimmu.2025.1614815.
|
| [16] |
Carey KM, Young CD, Clark AJ, et al. Subtype-specific analysis of gene co-expression networks and immune cell profiling reveals high grade serous ovarian cancer subtype linkage to variable immune microenvironment[J]. J Ovarian Res, 2024, 17(1):240. doi: 10.1186/s13048-024-01556-4.
pmid: 39627836
|
| [17] |
Amer H, Flanagan KL, Kampan NC, et al. Interleukin-6 Is a Crucial Factor in Shaping the Inflammatory Tumor Microenvironment in Ovarian Cancer and Determining Its Hot or Cold Nature with Diagnostic and Prognostic Utilities[J]. Cancers(Basel), 2025, 17(10):1691. doi: 10.3390/cancers17101691.
|
| [18] |
Cai D, Li J, Liu D, et al. Tumor-expressed B7-H3 mediates the inhibition of antitumor T-cell functions in ovarian cancer insensitive to PD-1 blockade therapy[J]. Cell Mol Immunol, 2020, 17(3):227-236. doi: 10.1038/s41423-019-0305-2.
pmid: 31611650
|
| [19] |
Mollaoglu G, Tepper A, Falcomatà C, et al. Ovarian cancer-derived IL-4 promotes immunotherapy resistance[J]. Cell, 2024, 187(26):7492-7510.e22. doi: 10.1016/j.cell.2024.10.006.
pmid: 39481380
|
| [20] |
Kader T, Lin JR, Hug CB, et al. Multimodal Spatial Profiling Reveals Immune Suppression and Microenvironment Remodeling in Fallopian Tube Precursors to High-Grade Serous Ovarian Carcinoma[J]. Cancer Discov, 2025, 15(6):1180-1202. doi: 10.1158/2159-8290.CD-24-1366.
|
| [21] |
Tang PW, Frisbie L, Hempel N, et al. Insights into the tumor-stromal-immune cell metabolism cross talk in ovarian cancer[J]. Am J Physiol Cell Physiol, 2023, 325(3):C731-C749. doi: 10.1152/ajpcell.00588.2022.
|
| [22] |
Gu R, Jiang L, Dai S, et al. Identification of exosome-related SERPINB1 as a novel predictor for tumor immune microenvironment and clinical outcomes in ovarian cancer[J]. J Ovarian Res, 2025, 18(1):65. doi: 10.1186/s13048-025-01589-3.
pmid: 40155942
|
| [23] |
Xiong Z, Huang Y, Cao S, et al. A new strategy for the treatment of advanced ovarian cancer: utilizing nanotechnology to regulate the tumor microenvironment[J]. Front Immunol, 2025, 16:1542326. doi: 10.3389/fimmu.2025.1542326.
|
| [24] |
Yu P, Wang Y, Yuan D, et al. Vascular normalization: reshaping the tumor microenvironment and augmenting antitumor immunity for ovarian cancer[J]. Front Immunol, 2023, 14:1276694. doi: 10.3389/fimmu.2023.1276694.
|
| [25] |
Ding J, Wang C, Sun Y, et al. Identification of an Autophagy-Related Signature for Prognosis and Immunotherapy Response Prediction in Ovarian Cancer[J]. Biomolecules, 2023, 13(2):339. doi: 10.3390/biom13020339.
|
| [26] |
Liu J, Xia B, Li B, et al. Leveraging machine learning models to evaluate immune infiltration in the ovarian cancer microenvironment: a single-cell analysis approach[J]. Discov Oncol, 2025, 16(1):1291. doi: 10.1007/s12672-025-03018-9.
pmid: 40632369
|
| [27] |
Schoutrop E, El-Serafi I, Poiret T, et al. Mesothelin-Specific CAR T Cells Target Ovarian Cancer[J]. Cancer Res, 2021, 81(11):3022-3035. doi: 10.1158/0008-5472.CAN-20-2701.
pmid: 33795251
|
| [28] |
Devlin MJ, Miller R, Laforets F, et al. The Tumor Microenvironment of Clear-Cell Ovarian Cancer[J]. Cancer Immunol Res, 2022, 10(11):1326-1339. doi: 10.1158/2326-6066.CIR-22-0407.
|
| [29] |
Qiu J, Ren T, Liu Q, et al. Dissecting the Distinct Tumor Microenvironments of HRD and HRP Ovarian Cancer: Implications for Targeted Therapies to Overcome PARPi Resistance in HRD Tumors and Refractoriness in HRP Tumors[J]. Adv Sci(Weinh), 2024, 11(38):e2309755. doi: 10.1002/advs.202309755.
|
| [30] |
Ding L, Kim HJ, Wang Q, et al. PARP Inhibition Elicits STING-Dependent Antitumor Immunity in Brca1-Deficient Ovarian Cancer[J]. Cell Rep, 2018, 25(11):2972-2980.e5. doi: 10.1016/j.celrep.2018.11.054.
pmid: 30540933
|
| [31] |
Rodriguez GM, Galpin K, Cook DP, et al. The Tumor Immune Profile of Murine Ovarian Cancer Models: An Essential Tool For Ovarian Cancer Immunotherapy Research[J]. Cancer Res Commun, 2022, 2(6):417-433. doi: 10.1158/2767-9764.crc-22-0017.
|
| [32] |
Wang Q, Ma X, Wu H, et al. Oncolytic adenovirus with MUC16-BiTE shows enhanced antitumor immune response by reversing the tumor microenvironment in PDX model of ovarian cancer[J]. Oncoimmunology, 2022, 11(1):2096362. doi: 10.1080/2162402X.2022.2096362.
|
| [33] |
Joy JD, Malacrida B, Laforêts F, et al. Human 3D Ovarian Cancer Models Reveal Malignant Cell-Intrinsic and -Extrinsic Factors That Influence CAR T-cell Activity[J]. Cancer Res, 2024, 84(15):2432-2449. doi: 10.1158/0008-5472.CAN-23-3007.
|
| [34] |
Arcieri M, Capezzali E, Restaino S, et al. Study of the Role of the Tumor Microenvironment in Ovarian Cancer (MICO): A Prospective Monocentric Trial[J]. Cancer Rep(Hoboken), 2025, 8(6):e70242. doi: 10.1002/cnr2.70242.
|
| [35] |
Yang H, Gu X, Fan R, et al. Deciphering tumor immune microenvironment differences between high-grade serous and endometrioid ovarian cancer to investigate their potential in indicating immunotherapy response[J]. J Ovarian Res, 2023, 16(1):223. doi: 10.1186/s13048-023-01284-1.
pmid: 37993916
|
| [36] |
Chen Y, Zhu X, Liu H, et al. The application of HER2 and CD47 CAR-macrophage in ovarian cancer[J]. J Transl Med, 2023, 21(1):654. doi: 10.1186/s12967-023-04479-8.
pmid: 37740183
|
| [37] |
Gitto SB, Ihewulezi C, Powell DJ Jr. Adoptive T cell therapy for ovarian cancer[J]. Gynecol Oncol, 2024, 186:77-84. doi: 10.1016/j.ygyno.2024.04.001.
pmid: 38603955
|